Immunovant Sciences Gmbh
Clinical trials sponsored by Immunovant Sciences Gmbh, explained in plain language.
-
New drug aims to tame Graves' disease Long-Term
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called IMVT-1402 in adults with Graves' disease, a condition where the immune system attacks the thyroid. The goal is to see if the drug can help patients stay healthy without needing other treatments. About 372 people who completed earlier studies will ta…
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New shot could tame lupus skin flares
Disease control OngoingThis study tests an experimental drug called IMVT-1402 in people with lupus-related skin rashes (subacute or chronic cutaneous lupus) that haven't gotten better with standard treatments. About 56 participants will receive either the drug or a placebo for 12 weeks, then all get th…
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug batoclimab aims to ease muscle weakness in myasthenia gravis
Disease control OngoingThis phase 3 trial tests batoclimab, a drug that blocks certain antibodies, in 240 adults with generalized myasthenia gravis (gMG). The study measures if batoclimab improves daily activities and muscle strength compared to a placebo. Participants receive injections weekly or bi-w…
Phase: PHASE3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New shot could help when arthritis drugs fail
Disease control OngoingThis study tests a new drug called IMVT-1402 in 120 adults with active, difficult-to-treat rheumatoid arthritis. Participants receive weekly injections of either the drug or a placebo. The goal is to see if the drug helps maintain symptom improvement over 28 weeks.
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for nerve disease: batoclimab safety trial expands
Disease control ENROLLING_BY_INVITATIONThis study checks the long-term safety of a drug called batoclimab for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and numbness. About 108 people who finished an earlier batoclimab study will get weekly injections fo…
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC